I you use any normal smartphone OS rather than say grapheneos then your location is tracked continously even if you turn off location tracking at user interface level and will be uploaded to Apple and/or Google periodically. Another less precise trail is gathered by cell towers. And this quite regardless of whether you use Google maps or some other map/navigation product.

Who cares if the nsec isn't all that secure in Nostr architecture and common practice among clients and apps?

Why is doing this with all the machinery of Nostr in the middle somehow more efficient and better than me granting directed permissioned use of my AI using standard auth and say normal encrypted HTTP request/reply? If anything it message interception or at least tracking who does inference where would be more likely putting NOSTR in the mix.

Rapamycin’s Immune-System Benefits Traced to DNA Damage Resilience A study in Aging Cell reports that low-dose rapamycin — the mTOR inhibitor that remains the single most robust life-extending pharmacological intervention known in mice — protects human immune cells against DNA damage. Working in human T cells and aged immune subsets, the team showed that rapamycin at doses well below immunosuppressive levels enhances the cellular response to DNA damage, reducing the accumulation of damaged cells that contribute to inflammaging and immune decline. Rapamycin’s life-extending effect has been reproduced across model organisms for two decades, but the mechanism in humans has been debated. Is it autophagy? Metabolic reprogramming? Direct effects on immune-cell senescence? This paper narrows the answer for one important cell type: at least part of the geroprotective effect operates through DNA-damage resilience in immune cells, distinct from the immunosuppression that rapamycin is prescribed for at higher doses. The distinction matters because low-dose and intermittent rapamycin dosing is now the subject of multiple ongoing human trials — the everolimus aging study, the ERAP protocol for Alzheimer’s, and off-label physician networks. If the DNA-damage-resilience mechanism holds up, it gives those trials a specific biomarker to track and provides a mechanistic case for pushing dose lower rather than higher, since immunosuppression is unwanted but DNA-damage protection appears at sub-immunosuppressive doses. Source: Aging Cell https://onlinelibrary.wiley.com/doi/10.1111/acel.70364

Life Biosciences Dosed the First Human with an Epigenetic Reprogramming Therapy Life Biosciences announced on 9 June that the first participant has been dosed in the Phase 1 clinical trial of ER-100, a partial epigenetic reprogramming therapy delivered by intravitreal injection. ER-100 targets optic neuropathies — open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy — but the significance runs beyond ophthalmology. This is the first-ever human clinical trial of a cellular rejuvenation therapy based on epigenetic reprogramming. The therapy uses three of the four classical Yamanaka factors — OCT4, SOX2, and KLF4, omitting c-Myc, which has been associated with tumor risk in mouse reprogramming studies. The idea is that transient expression of these transcription factors partially resets aged cells toward a younger epigenetic state without erasing their identity as the mature cell type they are supposed to be. In animal models, this has restored optic nerve function after injury and reversed vision loss in glaucoma models. The FDA cleared the IND in January 2026, making ER-100 the first partial-reprogramming therapy authorized for human study. The Phase 1 trial is small and focused on safety and tolerability, with visual function as a secondary endpoint. But because the safety profile of in vivo reprogramming is the single largest unknown in the entire cellular-rejuvenation field, the readout will be watched by every other epigenetic-reprogramming program. Source: Life Biosciences

Life Biosciences, Inc.

Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER‑100 for Optic Neuropathies

Lead epigenetic restoration therapy enters the clinic for glaucoma and NAION, targeting a root cause of age-related vision loss BOSTON, June 9, 202...

The wait is over: NSF–DOE Rubin Observatory, funded by the U.S. National Science Foundation and the U.S. Department of Energy's (DOE) Office of Science, is now capturing the cosmos in unprecedented detail, transforming the way we study the dynamic universe.

NSF - U.S. National Science Foundation

Action! NSF-DOE Vera C. Rubin Observatory begins capturing the greatest cosmic movie ever made

The wait is over: NSF–DOE Rubin Observatory, funded by the U.S. National Science Foundation and the U.S. Department of Energy's (DOE) Office...

Happy Inherent Inalienable Individual Rights Recognition Day!